secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001628280-24-035160
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo posts Q2 net loss $0.18/sh, cash $27.8M; signs Genentech deal for up to $1.9B
--------------------------------------------------------------------------------

- Signed global license with Genentech for zinc finger repressors targeting tau and STAC-BBB capsid; $50M near-term, up to $1.9B milestones plus royalties.
- Q2 net loss $36.1M ($0.18/sh) vs $114.5M ($0.66); revenue $0.3M down from $6.8M.
- Cash $27.8M at June 30; with Genentech $50M, runway into Q1 2025.
- Pfizer's Phase 3 hemophilia A gene therapy met primary endpoint; Sangamo eligible for up to $220M milestones and 14-20% royalties.
- Fabry disease: 33 patients dosed, 17 off ERT; eGFR improvement observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024035160/0001628280-24-035160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024035160/sgmo-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer